Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Trial of VDJ001 in Idiopathic Multicentric Castleman Disease
ChiCTR2600129962Phase 3Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in idiopathic multicentric Castleman disease (iMCD) comparing VDJ001 arm with Placebo arm (2 arms). Primary endpoint: Proportion of patients achieving sustained comprehensive CR or PR for at least 18 weeks. Started Aug 2026; status: recruiting.
02
Drugs
VDJ-001
03
Conditions
idiopathic multicentric Castleman disease (iMCD)
Beyond the preview
Go deeper on ChiCTR2600129962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129962.